Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

With crossover investors lining up to participate, biotechs Immuneering, Terns and Ikena each raised rounds that could augur upcoming public offerings.

The deals come as a host of biotechs will likely seek to test the public markets, continuing a trend after a record-setting year for NASDAQ listings in 2020...